Evidence map›Paper›PMID 42130708›Full record

ArticleJCEM case reports2026

Fournier gangrene in a patient with corticotrophinoma and diabetes treated with sodium-glucose cotransporter 2 inhibitor.

Beatriz Yukie Kagohara Elias, Paula Condé Lamparelli Elias, Francisco José Albuquerque de Paula, Ayrton Custodio Moreira, Marley Ribeiro Feitosa, Margaret de Castro

Abstract readCase Reports
In one paragraph

Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Beatriz Yukie Kagohara EliasDepartment of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto 14048-900, Brazil.ORCID https://orcid.org/0009-0001-8684-2799
Paula Condé Lamparelli EliasDepartment of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto 14048-900, Brazil.
Francisco José Albuquerque de PaulaDepartment of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto 14048-900, Brazil.
Ayrton Custodio MoreiraDepartment of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto 14048-900, Brazil.ORCID https://orcid.org/0000-0002-8096-6803
Marley Ribeiro FeitosaDepartment of Surgery and Anatomy, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto 14048-900, Brazil.
Margaret de CastroDepartment of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto 14048-900, Brazil.ORCID https://orcid.org/0000-0003-4932-4623

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypercortisolism induces immunosuppression, and infections represent the second leading cause of death among patients with Cushing syndrome. We report the case of an adult man with a silent corticotroph pituitary adenoma that evolved into a functioning adrenocorticotropic hormone-secreting tumor. The patient had diabetes mellitus and was treated with dapagliflozin. Prior to transsphenoidal adenomectomy, he developed Fournier gangrene, a necrotizing fasciitis of the perineal and genital regions. Infectious management included debridement, antibiotics, and hyperbaric oxygen therapy. After adequate control of the infection, pituitary surgery was performed, resulting in hypercortisolism remission. Although Cushing syndrome is well known to predispose patients to infections, the association between endogenous hypercortisolism and Fournier gangrene has been scarcely described in the literature. The present case highlights the risk of this severe soft tissue infection in patients with Cushing syndrome. Dapagliflozin and other sodium-glucose cotransporter 2 inhibitors have been investigated as potential contributors to Fournier gangrene in patients with diabetes mellitus, prompting a discussion about the safety of prescribing these agents in the setting of hypercortisolism.

Indexed as

corticotrophinomadiabetes mellitusFournier gangrenesodium–glucose cotransporter 2 inhibitor

Identifiers

PMID42130708
PMCPMC13166150

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.